NCT07089992View on ClinicalTrials.gov

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 11, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Sarcoma
Interventions
DRUG

Pembrolizumab

Q 6 weeks IV infusion Day 1 of each 6-week cycle, up to 8 doses

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

11553

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER